Sidley Austin represented BigHat Biosciences, Inc. in the transaction. BigHat Biosciences, Inc. (“BigHat”), announced a licensing collaboration with Synaffix B.V. (“Synaffix”), a Lonza company (SWX:LONN). BigHat’s...
BigHat Biosciences’ Licensing Collaboration With Synaffix B.V.
BigHat Biosciences’ Collaboration with Janssen Biotech
Sidley Austin represented BigHat Biosciences in the transaction. BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced its collaboration...
Novo Nordisk’s Partnership with Evotec SE to Launch Translational Drug Discovery Accelerator
Sidley Austin LLP represented Novo Nordisk Inc. in the matter. Novo Nordisk (NYSE: NVO) announced its collaboration with Evotec SE (NASDAQ: EVO) to launch LAB eN² (pronounced Lab...
Tyra Biosciences’ $172.8 Million Initial Public Offering
Latham & Watkins represented Tyra Biosciences in the offering while Sidley advised the underwriters. Tyra Biosciences, Inc. has announced the pricing of its upsized initial public offering of...
Interius BioTherapeutics’ US$76 Million Series A financing.
Sidley Austin LLP advised Interius BioTherapeutics on the deal. Interius BioTherapeutics, a preclinical stage gene therapy company developing a paradigm-shifting platform for in vivo cell-specific gene...